Immunomedics, Inc., (NASDAQ:IMMU) on 21 May 2014 reported a stabilization of disease, as measured by computed tomography (CT) according to RECIST criteria, in pancreatic cancer patients with advanced disease and who failed 1-5 prior therapies. In a group of 13 CT-assessable patients receiving repeated doses of the Company’s investigational antibody-drug conjugate (ADC), IMMU-132, a median time-to-progression of 12.7 weeks was reported (range 4.3-21.4 weeks), which … Continue reading Volatile Stocks: Immunomedics (NASDAQ:IMMU), MagneGas Corporation (NASDAQ:MNGA), Pacific Sunwear of California (NASDAQ:PSUN), Gogo Inc (NASDAQ:GOGO), LiveDeal Inc (NASDAQ:LIVE)